

(19) World Intellectual Property Organization
International Bureau



162162

(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072090 A1

(51) International Patent Classification⁷: **A61K 31/4184**,
31/4439, 31/422, A61P 35/00, 11/06, 37/08, C07D 235/18,
401/12, 403/12, 413/12, 401/14, 403/14

Diego, CA 92130 (US). **MAJOR, Michael, W.**; 612 West
Kenilworth Circle, Mequon, WI 53092 (US).

(21) International Application Number: PCT/US02/06801

(74) Agent: **DELANEY, Karoline, A.**; Knobbe, Martens, Ol-
son & Bear, LLP, 620 Newport Center Drive, 16th Floor,
Newport Beach, CA 92660 (US).

(22) International Filing Date: 28 February 2002 (28.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/275,260 12 March 2001 (12.03.2001) US
10/090,044 27 February 2002 (27.02.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, CZ (utility model), DE, DE (utility model), DK, DK
(utility model), DM, DZ, EC, EE, EE (utility model), ES,
FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility
model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.




(71) Applicant: **AVANIR PHARMACEUTICALS [US/US]**;
11388 Sorrento Valley Road, Suite 200, San Diego, CA
92121 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent

(72) Inventors: **SIRCAR, Jagadish, C.**; 4832 Riding Ridge
Road, San Diego, CA 92130 (US). **RICHARDS, Mark,**
L.; 11042 West Ocean Air Drive, Apartment No. 345, San

[Continued on next page]

(54) Title: BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION



(57) Abstract: The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

WO 02/072090 A1



ACTION

(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*